Study characteristics |
Methods |
Experimental study conducted in Texas, USA during the 1994 to 1995 influenza season, randomised, placebo‐controlled trial; randomisation method and allocation concealment were not described. Participants were allocated to receive ascending doses (15 ug/45 ug/135 ug) of antigen. Only 15 ug vaccine was included in analysis. Follow‐up period was 48 hours after vaccination. |
Participants |
21 ambulatory, medically stable people, 65 years or older |
Interventions |
Parenteral monovalent subvirion 15 ug (9 participants) and purified haemagglutinin 15 ug (12 participants) influenza vaccine: A/Singapore/6/86 |
Outcomes |
Discomfort, erythema/induration, headache, malaise without further description |
Notes |
Different vaccines (haemagglutinin and subvirion) were analysed as a single "treatment group". |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Allocation concealment (selection bias) |
Unclear risk |
D ‐ Not used |